NeurAxis, Inc., today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules.

NeurAxis, Inc., awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

NeurAxis, Inc., today announced results for the first quarter 2025 for the period ended March 31, 2025.

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time

NeurAxis, Inc., to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025

NeurAxis, Inc., today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.

CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

Revenues in 4Q24 increased approximately 50% versus 4Q23 Cash balance as of 12/31/24 was approximately